Citius Pharmaceuticals, Inc. CTXR

$CTXR/CTOR - Most of u people are clueless and really have NO idea about what’s going on. There is a complete plan in effect and there will be NO RS!! Although you think otherwise, Leonard & his team have this all planned out—with enough working capital to easily carry them until the Lymphir $$$ starts coming in. Furthermore, the $1 pps x 10 days for compliance is NOT the only factor for NASDAQ listing. There are several things that come into play and—trust me—management has it all under control.

So, either sell your few hundred shares, get out and quit complaining. Or, sit back, be patient and make some REAL money over the next few months. Short term, the market just has to figure out how to deal with the spinoff & CTXR existing at the same time. Once that happens there will be a steady rise, or maybe a big pharma buyout any day now. There will be NO RS!?

$CTOR- It’s happening folks!! All set up and ready to rumble at any moment?? Maybe today??? ??https://news.google.com/rss/articles/CBMiTkFVX3lxTFAxRGQ4ZDVGLU40cXBZY1JYblZDX1g3SWZrUVZCVDNYWDBjQzUxZV9LVXAxU0N2QzdFVUtLNWFYeG8xNXgwUlBZSlZOTDRvZw

$CTXR-HTTPS://www.prnewswire.com/news-releases/citius-pharmaceuticals-receives-fda-approval-for-lymphir-denileukin-diftitox-cxdl-immunotherapy-for-the-treatment-of-adults-with-relapsed-or-refractory-cutaneous-t-cell-lymphoma-302217630.html

$CTXR- Hey folks…don’t obsess over the $1 pps for NASDAQ compliance. There are several other factors that come into play for NASDAQ listing…ie, assets of company, and some other variables, etc, etc. Remember, Citius (CTXR) owns 90% of TENKU (which will become CTOR). Therefore, the “assets” of CTXR, plus whatever other NASDAQ requirements come into play, will likely maintain their eligibility, even if the CTXR pps isn’t over $1 for ten days.

CTXR don’t miss the potential AUGUST 13 FDA Approves Biotech Stocks Race Towards Solutions for Cutaneous T-Cell Lymphoma (CTCL)
Biotech stocks are racing towards solutions for Cutaneous T-Cell Lymphoma (CTCL), with the market projected to reach $1.38 Billion by 2030.
Citius Pharmaceuticals (NASDAQ: CTXR) is approaching the FDA target date of August 13th for its LYMPHIR product candidate.
The FDA has accepted the resubmission of Citius' Biologics License Application (BLA) for LYMPHIR, an IL-2-based immunotherapy for relapsed or refractory CTCL. EF Hutton initiated coverage of CTXR with a Buy recommendation and a $6.00 price target.
Other companies like Soligenix and Takeda-Pfizer are also making progress in CTCL and lymphoma treatments, highlighting the growing interest and potential in this market.

This week, EF Hutton initiated coverage of Citius Pharmaceuticals (NASDAQ: CTXR) with a Buy recommendation with a price target of $6.00. Analyst Jason Kolbert sees the stock as low risk - high reward based on their two late stage therapeutics, Mino-Lok and LYMPHIR. He also notes that a planned IPO for LYMPHIR this summer, in addition to an early August PDUFA should be catalysts to unlock value for Citius.

$CTXR- It’s gonna be a good Wednesday ?? Enjoy the ride. ??https://dwinnex.com/market-recap-citius-pharmaceuticals-inc-ctxrs-positive-momentum-closing-at-0-93/

$CTXR- Good premarket action??Let’s go! https://www.uspostnews.com/2024/07/22/should-investors-be-concerned-about-citius-pharmaceuticals-inc-ctxr/

$CTXR- Gonna be a GOOD week folks!!??

$CTXR - > 2M in first 2 hrs of trading ???????